Sarepta Therapeutics (NASDAQ:SRPT) Given New $200.00 Price Target at Robert W. Baird

Sarepta Therapeutics (NASDAQ:SRPT) had its target price upped by Robert W. Baird from $170.00 to $200.00 in a research report sent to investors on Friday morning, Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock.

A number of other research analysts have also recently commented on SRPT. Oppenheimer raised Sarepta Therapeutics from a market perform rating to an outperform rating and set a $180.00 target price on the stock in a research note on Tuesday, May 14th. Barclays increased their price objective on Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an overweight rating in a research note on Thursday, February 29th. TheStreet raised Sarepta Therapeutics from a d rating to a c- rating in a research note on Monday, March 4th. Royal Bank of Canada reissued a sector perform rating and issued a $142.00 price objective (down previously from $157.00) on shares of Sarepta Therapeutics in a research note on Tuesday, May 28th. Finally, Wedbush reissued an outperform rating and issued a $224.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus target price of $177.65.

Sarepta Therapeutics Trading Up 30.1 %

SRPT opened at $160.72 on Friday. The stock has a market cap of $15.19 billion, a price-to-earnings ratio of 1,461.09 and a beta of 0.96. The stock’s 50 day moving average price is $125.56 and its 200-day moving average price is $119.73. Sarepta Therapeutics has a one year low of $55.25 and a one year high of $173.25. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.44 and a current ratio of 4.05.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.84. The firm had revenue of $413.50 million for the quarter, compared to analysts’ expectations of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The company’s quarterly revenue was up 63.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.44) earnings per share. On average, equities analysts forecast that Sarepta Therapeutics will post 2.99 EPS for the current year.

Insiders Place Their Bets

In other news, insider Dallan Murray sold 3,635 shares of the stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the completion of the sale, the insider now owns 18,125 shares in the company, valued at approximately $2,537,500. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 7.70% of the stock is owned by company insiders.

Institutional Trading of Sarepta Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mather Group LLC. purchased a new stake in shares of Sarepta Therapeutics during the 1st quarter valued at $28,000. Riggs Asset Managment Co. Inc. increased its position in shares of Sarepta Therapeutics by 125.0% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 125 shares during the period. New Covenant Trust Company N.A. acquired a new position in shares of Sarepta Therapeutics in the 1st quarter valued at $32,000. Cary Street Partners Investment Advisory LLC increased its position in shares of Sarepta Therapeutics by 154.0% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 154 shares during the period. Finally, Principal Securities Inc. acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $26,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.